Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis

Cancer Biology and Therapy

Volumn 11, Issue 12, 2011, Pages 995-1000

  Chu, Xiang Yang ^a   Hou, Xiao Bin ^a   Song, Wei An ^a   Xue, Zhi Qiang ^a   Wang, Bo ^a   Zhang, Lian Bin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CEA; Cyfra21 1; Diagnosis; Lung cancer; NSE; SCC; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; REFERENCE VALUES; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79958804951     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.12.15526     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108.
2. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23:143-52. (Pubitemid 29123884)
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-49.
4. Henschke CI, Yankelevitz DF. CT screening for lung cancer: update 2007. Oncologist 2008; 13:65-78.
5. Krotz D. Low-dose CT screening reduces lung cancer deaths. Diagn Imaging (San Franc) 2000; 7-9.
6. Yankelevitz D. CT screening for lung cancer. AJR Am J Roentgenol 2003; 180:1736-7.
7. Finley RJ, Clifton J, Mayo J. Image-guided video-assisted thoracoscopic resection of small peripheral lung nodules. Adv Surg 2005; 39:263-84. (Pubitemid 41737965)
8. Sortini D, Carcoforo P, Feo CV, Carrella G, Pozza E, Sortini A. Radiological examination for peripheral lung cancers and benign nodules less than 10 mm. Lung Cancer 2004; 45:393-4.
9. Kumarasinghe P, Jayasundera CI. Cytological diagnosis of bronchial malignancies using the fibreoptic bronchoscope. Ceylon Med J 1992; 37:41-3.
10. Podbielski FJ, Rodriguez HE, Brown AM, Blecha MJ, Salazar MR, Connolly MM. Percutaneous biopsy in evaluation of lung nodules. JSLS 2004; 8:213-6.
11. Raj Behl P, Hilton CJ, Holden MP. Mediastinoscope: another use. J Cardiovasc Surg (Torino) 1986; 27:236-7. (Pubitemid 16134012)
12. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007; 84:959-65.
13. Vinolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 1998; 18:631-4. (Pubitemid 28174884)
14. Sanchez De Cos J, Masa F, de la Cruz JL, Disdier C, Vergara C. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest 1994; 105:773-6. (Pubitemid 24088455)
15. Niewoehner DE, Rubins JB. Clinical utility of tumor markers in the management of non-small cell lung cancer. Methods Mol Med 2003; 75:135-41.
16. Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23:4277-81. (Pubitemid 37474933)
17. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010; 30:3099-102.
18. Holdenrieder S, Von Pawel J, Duell T, Feldmann K, Raith H, Schollen A, et al. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res 2010; 30:1855-62.
19. Emin Erbaycu A, Gunduz A, Batum O, Zeren Ucar Z, Tuksavul F, Zeki Guclu S. Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol 2010; 46:364-9.
20. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86:1488-95. (Pubitemid 29489782)
21. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1 and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48:1931-7. (Pubitemid 35222751)
22. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21-1 and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology 2010; 42:224-8.
23. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role. Chest 1995; 108:163-9.
24. Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996; 77:1274-7. (Pubitemid 26103349)
25. Bates J, Rutherford R, Divilly M, Finn J, Grimes H, O'Muircheartaigh I, et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 1997; 10:2535-8. (Pubitemid 28048628)
26. Lagarde A, Forgach T, Nagy D, Nagy K, Vasas S, Janoki GA. Diagnostic sensitivity of three tumour markers in non-small cell lung cancer: a pilot study. Nucl Med Rev Cent East Eur 2000; 3:139-42.
27. Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, et al. Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 2001; 32:137-44. (Pubitemid 32372606)
28. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med 1996; 15:969-86.
29. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008; 29:371-80.
30. Gaarenstroom KN, Bonfrer JM, Korse CM, Kenter GG, Kenemans P. Value of Cyfra 21-1, TPA and SCCAg in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res 1997; 17:2955-8.
31. Brockmann JG, St. Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000; 6:4249-52.
32. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7:2357-62. (Pubitemid 32751636)
33. Odagiri E. Neuron specific enolase (NSE). Nippon Rinsho 1999; 57:540-2.
34. Takahashi H, Kurishima K, Ishikawa H, Kagohashi K, Kawaguchi M, Satoh H. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. Anticancer Res 2010; 30:3833-7.
35. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005; 40:90-7.
36. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136:260-71.